[Special Stock] Syntekabio Surges on Completion of Korea's First Quantum-Coupled AI Bio Supercomputer

Syntekabio is showing strong performance. This is interpreted as being influenced by the news that it will operate Korea's first artificial intelligence (AI) bio supercomputer.

As of 1:40 PM on the 12th, Syntekabio is trading at 12,770 KRW, up 4.42% compared to the previous day.

According to the industry, Syntekabio's AI Bio Supercomputer (ABS) Center, built within the Daejeon International Science Business Belt, has obtained usage approval. The relocation of supercomputing equipment previously located at the Seoul Guro Center has been completed, and after resuming equipment use and stabilization, full-scale operation is scheduled for the end of October.

Syntekabio is preparing genome big data and AI new drug platform services covering the entire new drug development cycle based on its own cloud supercomputing infrastructure. This includes services from the discovery of effective substances required throughout the new drug development cycle to preclinical services (DDC), as well as genome biomarker discovery and detection services.

Earlier, Syntekabio announced in August that it had signed a strategic business agreement (MOU) with Polaris Quantum Biotech in the United States. Polaris QB is a quantum computing-based new drug development company located in North Carolina, USA. It owns QuADD, a new drug candidate generation platform based on a quantum annealer.

Shahar Keinan, founder and CEO of Polaris QB, stated, "By providing new drug development services such as Syntekabio's cloud supercomputing infrastructure and genome-based AI platform, we expect to quickly and efficiently discover lead compounds."

This content was produced with the assistance of AI translation services.